We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ivax has received final FDA approval to market a version of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucovance (glyburide/metformin HCl), the firm said Feb. 19.
Spending on prescription drugs is expected to continue to decline over the next decade, according to a report released Feb. 11 by the Centers for Medicare & Medicaid Services (CMS).
Generic drugmaker Mylan Laboratories has rejoined Pennsylvania’s $400 million prescription drug discount program on the condition that state officials work to lower the required rebate on generic drugs to 11 percent.
Eli Lilly has warned doctors and psychiatrists that using its antipsychotic drug Zyprexa (olanzapine) to treat elderly patients with dementia can increase their risk of stroke and death.
Overall prescription drug sales in the U.S. grew 11.5 percent to $216.4 billion last year despite challenges from new OTC products, concerns about hormone replacement therapies and the reimportation of drugs from Canada, according to IMS Health.
A campaign funded by the National Institutes of Health (NIH) to educate doctors about the option of prescribing low-cost alternatives to antihypertensive drugs is taking direct aim at the bottom lines of pharmaceutical manufacturers.
Two national associations that oversee drug wholesale distributors have ratcheted up their requirements for membership and licensure to help in the battle against counterfeit pharmaceuticals.
Reversing an earlier decision, generic drugmaker Mylan Laboratories has rejoined Pennsylvania’s $400 million prescription drug discount program on the condition that state officials work to lower the required rebate on generic drugs to 11 percent.
The cross hairs of a campaign funded by the National Institutes of Health (NIH) to educate doctors about the option of prescribing low-cost alternatives to antihypertensive drugs are centered squarely on the bottom lines of pharmaceutical manufacturers.